Cited 11 times in
Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상학 | - |
dc.date.accessioned | 2017-11-02T08:28:11Z | - |
dc.date.available | 2017-11-02T08:28:11Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154501 | - |
dc.description.abstract | In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has been higher than in previous reports. Although cascade genetic screening is a good option for efficient identification of affected patients, diagnosis using only clinical criteria is more common in real clinical practice. Cardiovascular risk is much higher in FH patients due to longstanding low density lipoprotein cholesterol (LDL-C) burden and is also influenced by other risk factors. Although guidelines emphasize aggressive LDL-C reduction, the majority of patients cannot reach the LDL-C goal by conventional pharmacotherapy. Novel therapeutics such as proprotein convertase subtilisin/kexin type 9 inhibitors have shown strong lipid lowering efficacy and are expected to improve treatment results in FH patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Endocrine Society | - |
dc.relation.isPartOf | Endocrinology and Metabolism (대한내분비학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.identifier.doi | 10.3803/EnM.2017.32.1.36 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J00773 | - |
dc.relation.journalsince | 2011~ | - |
dc.identifier.pmid | 28116871 | - |
dc.relation.journalbefore | ~2010 Journal of Korea Society of Endocrinology (대한내분비학회지) | - |
dc.subject.keyword | Coronary disease | - |
dc.subject.keyword | Genetics | - |
dc.subject.keyword | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keyword | Hyperlipoproteinemia type II | - |
dc.subject.keyword | PCSK9 protein, human | - |
dc.contributor.alternativeName | Lee, Snag Hak | - |
dc.contributor.affiliatedAuthor | Lee, Snag Hak | - |
dc.citation.title | Endocrinology and Metabolism (대한내분비학회지) | - |
dc.citation.volume | 32 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 36 | - |
dc.citation.endPage | 40 | - |
dc.identifier.bibliographicCitation | Endocrinology and Metabolism (대한내분비학회지), Vol.32(1) : 36-40, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 43073 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.